Shingrix vaccine for people with CLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether the Shingrix vaccine prevents shingles in people with CLL (a type of blood cancer). It will look at how well the vaccine works and helps your immune system fight the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of CLL, SLL, or CLL-like MBL (a blood condition that may turn into CLL).
- Your CLL is either early-stage and not progressing, or active/advanced and not yet treated, or you've been on targeted therapy (like ibrutinib, acalabrutinib, or venetoclax) for at least 6 months.
- You are 18 or older and eligible to receive the Shingrix shingles vaccine through the Italian National Health System.
- You have not had a shingles infection or reactivation in the past year.
- You have never received the Shingrix vaccine before.
- You are not pregnant, do not have a serious active infection, and have not had IVIG treatment or certain other immunosuppressive therapies recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.
This study tests whether an extra dose of the Shingrix shingles vaccine can boost protection in people who have had a solid-organ transplant. If you already received both doses of Shingrix after your transplant, this trial will give you an additional dose to see if it further strengthens your immune response.
This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.
This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
This study tests how well the shingles vaccine (Shingrix) works in people with lupus who take immune-suppressing medications. Researchers want to understand if the vaccine provides good protection in lupus patients, since their immune systems work differently.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.